血清基质金属蛋白酶活性与动脉粥样硬化斑块稳定性的实验观察  

The Study of the Relations Between Activity of Serum Matrix Metalloproteinase and Plaque Stability by Experiment

作　　者：赵慧颖[1] 徐宝华[2] 马小欣[1] 

机构地区：[1]吉林大学第一临床医院,吉林长春130021 [2]大连市第三人民医院

出　　处：《中国微循环》2007年第3期163-167,共5页Journal of Chinese Microcirculation

基　　金：吉林省科技厅课题(编号:200505222)

摘　　要：目的观察血清MMP-2、MMP-9在不同时期的兔动脉粥样硬化动物模型中的变化,研究其影响因素及与斑块稳定性的关系。方法将30只长耳白兔随机分为3组:普通饮食组(n=10),高脂饮食组(n=10),球囊损伤+高脂饮食组(n=10),3个月后以中国斑点蝰蛇毒和组胺触发使斑块破裂。其间监测血脂情况,并行血清MMP-2、MMP-9检测。动物处死后查找动脉硬化斑块行病理检测。结果普通饮食组实验中各检测项目均无明显差异。高脂饮食及球囊损伤+高脂饮食组一个月后血脂明显升高。药物触发后高脂饮食组血清MMP-9活性明显增加,球囊损伤+高脂饮食组血清MMP-2、MMP-9活性均明显增加。结论在兔动脉粥样硬化的动物模型中,斑块处于不稳定状态时血清MMP-9活性明显增加,而MMP-2的活性升高可能与内皮机械损伤有关。Objective To study the influential factors of MMP-2, MMP-9and the relations between these factors and plaque stability in different period of atherosclerosis by establishing atherosclerotic rabbit animal models. Methods 30 rabbits were divided into 3 groups at random： control group（ n = 10） ; atherogenic diet group（ n = 10） ; balloon-injury ＋ atherogenic diet group（ n = 10）. 3 months later the three groups underwent pharmacological triggering with Chinese Russell＇ s viper venom and histamine. The lipid concentrations and the levels of MMP-2, MMP-9 in the serum were obtained at different periods, and pathologic changes were observed. Results In the control group, there was no difference in all observed items at different periods. In atherogenic diet group, the activity of serum MMP-9 obviously increased after pharmacological triggering . In balloon-injury ＋ atherogenic diet group, the activity of serum MMP-2 and MMP-9 markedly increased after pharmacological triggering. Compared with atherogenic diet group, the activity of serum MMP-2 was higher in balloon-injury ＋ atherogenic diet group after pharmacological triggering. Conclusion In this animal model, there was increase of MMP-9 activity when the atherosclerotic plaques were unstable, the mechanical injury in endothelium was an influential factor of MMP- 2activity.

关 键 词：基质金属蛋白酶 动脉粥样硬化 斑块稳定性 

分 类 号：R734.2[医药卫生—肿瘤]